Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial
COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in no...
Uložené v:
| Vydané v: | Circulation (New York, N.Y.) Ročník 147; číslo 25; s. 1891 |
|---|---|
| Hlavní autori: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
20.06.2023
|
| Predmet: | |
| ISSN: | 1524-4539, 1524-4539 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor, we conducted the PREVENT-HD double-blind, placebo-controlled randomized trial (A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19] Infection).
PREVENT-HD was conducted between August 2020 and April 2022 at 14 US integrated health care delivery networks. A virtual trial design used remote informed consent and clinical monitoring and facilitated data collection through electronic health record integration with a cloud-based research platform. Nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor were enrolled and randomly assigned to either 10 mg of oral rivaroxaban or placebo daily for 35 days. The primary efficacy outcome was time to first occurrence of a composite of symptomatic venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, non-central nervous system systemic arterial embolism, hospitalization, or death through day 35. The principal safety end point was International Society on Thrombosis and Hemostasis critical-site or fatal bleeding. The last study visit was on day 49.
The study was terminated prematurely because of enrollment challenges and a lower-than-expected blinded pooled event rate. A total of 1284 patients underwent randomization with complete accrual of primary events through May 2022. No patients were lost to follow-up. The primary efficacy outcome occurred in 22 of 641 in the rivaroxaban group and 19 of 643 in the placebo group (3.4% versus 3.0%; hazard ratio, 1.16 [95% CI, 0.63-2.15];
=0.63). No patient in either group experienced critical-site or fatal bleeding. One patient receiving rivaroxaban had a major bleed.
The study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis did not appear to reduce a composite end point of venous and arterial thrombotic events, hospitalization, and death.
URL: https://www.
gov; Unique identifier: NCT04508023. |
|---|---|
| AbstractList | COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor, we conducted the PREVENT-HD double-blind, placebo-controlled randomized trial (A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19] Infection).
PREVENT-HD was conducted between August 2020 and April 2022 at 14 US integrated health care delivery networks. A virtual trial design used remote informed consent and clinical monitoring and facilitated data collection through electronic health record integration with a cloud-based research platform. Nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor were enrolled and randomly assigned to either 10 mg of oral rivaroxaban or placebo daily for 35 days. The primary efficacy outcome was time to first occurrence of a composite of symptomatic venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, non-central nervous system systemic arterial embolism, hospitalization, or death through day 35. The principal safety end point was International Society on Thrombosis and Hemostasis critical-site or fatal bleeding. The last study visit was on day 49.
The study was terminated prematurely because of enrollment challenges and a lower-than-expected blinded pooled event rate. A total of 1284 patients underwent randomization with complete accrual of primary events through May 2022. No patients were lost to follow-up. The primary efficacy outcome occurred in 22 of 641 in the rivaroxaban group and 19 of 643 in the placebo group (3.4% versus 3.0%; hazard ratio, 1.16 [95% CI, 0.63-2.15];
=0.63). No patient in either group experienced critical-site or fatal bleeding. One patient receiving rivaroxaban had a major bleed.
The study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis did not appear to reduce a composite end point of venous and arterial thrombotic events, hospitalization, and death.
URL: https://www.
gov; Unique identifier: NCT04508023. COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor, we conducted the PREVENT-HD double-blind, placebo-controlled randomized trial (A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19] Infection).BACKGROUNDCOVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor, we conducted the PREVENT-HD double-blind, placebo-controlled randomized trial (A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19] Infection).PREVENT-HD was conducted between August 2020 and April 2022 at 14 US integrated health care delivery networks. A virtual trial design used remote informed consent and clinical monitoring and facilitated data collection through electronic health record integration with a cloud-based research platform. Nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor were enrolled and randomly assigned to either 10 mg of oral rivaroxaban or placebo daily for 35 days. The primary efficacy outcome was time to first occurrence of a composite of symptomatic venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, non-central nervous system systemic arterial embolism, hospitalization, or death through day 35. The principal safety end point was International Society on Thrombosis and Hemostasis critical-site or fatal bleeding. The last study visit was on day 49.METHODSPREVENT-HD was conducted between August 2020 and April 2022 at 14 US integrated health care delivery networks. A virtual trial design used remote informed consent and clinical monitoring and facilitated data collection through electronic health record integration with a cloud-based research platform. Nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor were enrolled and randomly assigned to either 10 mg of oral rivaroxaban or placebo daily for 35 days. The primary efficacy outcome was time to first occurrence of a composite of symptomatic venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, non-central nervous system systemic arterial embolism, hospitalization, or death through day 35. The principal safety end point was International Society on Thrombosis and Hemostasis critical-site or fatal bleeding. The last study visit was on day 49.The study was terminated prematurely because of enrollment challenges and a lower-than-expected blinded pooled event rate. A total of 1284 patients underwent randomization with complete accrual of primary events through May 2022. No patients were lost to follow-up. The primary efficacy outcome occurred in 22 of 641 in the rivaroxaban group and 19 of 643 in the placebo group (3.4% versus 3.0%; hazard ratio, 1.16 [95% CI, 0.63-2.15]; P=0.63). No patient in either group experienced critical-site or fatal bleeding. One patient receiving rivaroxaban had a major bleed.RESULTSThe study was terminated prematurely because of enrollment challenges and a lower-than-expected blinded pooled event rate. A total of 1284 patients underwent randomization with complete accrual of primary events through May 2022. No patients were lost to follow-up. The primary efficacy outcome occurred in 22 of 641 in the rivaroxaban group and 19 of 643 in the placebo group (3.4% versus 3.0%; hazard ratio, 1.16 [95% CI, 0.63-2.15]; P=0.63). No patient in either group experienced critical-site or fatal bleeding. One patient receiving rivaroxaban had a major bleed.The study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis did not appear to reduce a composite end point of venous and arterial thrombotic events, hospitalization, and death.CONCLUSIONSThe study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis did not appear to reduce a composite end point of venous and arterial thrombotic events, hospitalization, and death.URL: https://www.REGISTRATIONURL: https://www.gov; Unique identifier: NCT04508023.CLINICALTRIALSgov; Unique identifier: NCT04508023. |
| Author | Bull, Todd M Lipardi, Concetta Go, Alan S Weng, Stephen Barnathan, Elliot S Hsia, Judith Towner, William J Spyropoulos, Alex C Goldin, Mark Bonaca, Marc P Piazza, Gregory |
| Author_xml | – sequence: 1 givenname: Gregory orcidid: 0000-0003-1407-5276 surname: Piazza fullname: Piazza, Gregory organization: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.P.) – sequence: 2 givenname: Alex C orcidid: 0000-0002-3175-461X surname: Spyropoulos fullname: Spyropoulos, Alex C organization: Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY (A.C.S.) – sequence: 3 givenname: Judith orcidid: 0000-0002-3413-7836 surname: Hsia fullname: Hsia, Judith organization: Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, Aurora (J.H., M.P.B.) – sequence: 4 givenname: Mark surname: Goldin fullname: Goldin, Mark organization: Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY (M.G.) – sequence: 5 givenname: William J surname: Towner fullname: Towner, William J organization: Departments of Clinical Science (W.J.T.), Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA – sequence: 6 givenname: Alan S orcidid: 0000-0001-9109-0811 surname: Go fullname: Go, Alan S organization: Departments of Epidemiology, Biostatistics and Medicine, University of California, San Francisco (A.S.G.) – sequence: 7 givenname: Todd M surname: Bull fullname: Bull, Todd M organization: Pulmonary Sciences and Critical Care Medicine and Cardiology, University of Colorado School of Medicine, Aurora (T.M.B.) – sequence: 8 givenname: Stephen surname: Weng fullname: Weng, Stephen organization: Janssen Research and Development, Statistical Decision Sciences, Cardiovascular and Metabolism, High Wycombe, UK (S.W.) – sequence: 9 givenname: Concetta surname: Lipardi fullname: Lipardi, Concetta organization: Janssen Research and Development, Clinical Development, Raritan, NJ (C.L., E.S.B.) – sequence: 10 givenname: Elliot S orcidid: 0000-0001-7744-1486 surname: Barnathan fullname: Barnathan, Elliot S organization: Janssen Research and Development, Clinical Development, Raritan, NJ (C.L., E.S.B.) – sequence: 11 givenname: Marc P orcidid: 0000-0002-9860-3584 surname: Bonaca fullname: Bonaca, Marc P organization: Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, Aurora (J.H., M.P.B.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37154020$$D View this record in MEDLINE/PubMed |
| BookMark | eNpN0F1LwzAUBuAgE_ehf0HinRfrTNKkH96VbrrCsDI6vSxpm7BIm9R-DN29_9sOFbw4vIeXh3NxpmCkjRYA3GC0wNjBd2G0DXebIInip2AdLDCxF8ixfYTPwAQzQi3KbH_0bx-Dadu-ITQol12Ase1iRhFBE_C1VQfemA-ecQ2laeBzIw5Cd8poaCRM9o2pMtOpHK5OdTuHa9PWquOlOvKTmkOuC7gUvNtDpWHcd_XQnyh8VUMXxi_R0sL-PQzgdqCmUkdRwLBUWuW8hEmjeHkJziUvW3H1mzOwe1gl4draxI9RGGysnDo-tYbJCuzlGBUO9ZGkOaeMYDd3C-lw5klqc-6KwvaYjb3CQXmGJJGu9DyUMYnIDNz-3K0b896Ltksr1eaiLLkWpm9T4mHMHNcm7kCvf2mfVaJI60ZVvPlM_15HvgGI5HUE |
| CitedBy_id | crossref_primary_10_1016_j_jtha_2024_02_011 crossref_primary_10_1016_j_thromres_2024_02_021 crossref_primary_10_1016_j_rpth_2024_102534 crossref_primary_10_1136_bmj_2024_081165 crossref_primary_10_7189_jogh_14_05015 crossref_primary_10_3390_ijms25168727 crossref_primary_10_1007_s11239_024_02966_3 crossref_primary_10_1016_j_rpth_2024_102613 crossref_primary_10_1016_j_thromres_2023_08_009 crossref_primary_10_1016_j_thromres_2024_04_007 crossref_primary_10_1055_s_0043_1774795 crossref_primary_10_1055_a_2216_5848 crossref_primary_10_1097_JS9_0000000000001307 crossref_primary_10_1136_bmjopen_2024_088917 crossref_primary_10_3390_v16111677 |
| ContentType | Journal Article |
| CorporateAuthor | PREVENT-HD Investigators |
| CorporateAuthor_xml | – name: PREVENT-HD Investigators |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1161/CIRCULATIONAHA.123.063901 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1524-4539 |
| ExternalDocumentID | 37154020 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .-D .3C .XZ .Z2 01R 0R~ 0ZK 18M 1J1 29B 2FS 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAAV AAAXR AAFWJ AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAUEB AAWTL AAXQO ABASU ABBUW ABDIG ABJNI ABOCM ABPMR ABPXF ABQRW ABVCZ ABXVJ ABXYN ABZAD ABZZY ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACLDA ACOAL ACRKK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADCYY ADGGA ADHPY AE3 AE6 AEBDS AENEX AFBFQ AFCHL AFDTB AFEXH AFMBP AFNMH AFSOK AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC ASPBG AVWKF AYCSE AZFZN BAWUL BOYCO BQLVK BYPQX C45 CGR CS3 CUY CVF DIK DIWNM DU5 E3Z EBS ECM EEVPB EIF ERAAH EX3 F2K F2L F2M F2N F5P FCALG GNXGY GQDEL GX1 H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 K-A K-F K8S KD2 KMI KQ8 L-C L7B N9A NPM N~7 N~B O9- OAG OAH OBH OCB ODMTH OGEVE OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P2P PQQKQ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WOQ WOW X3V X3W XXN XYM YFH YOC YSK YYM YZZ ZFV ZY1 ~H1 7X8 ADKSD ADSXY |
| ID | FETCH-LOGICAL-c4694-694bd18c10d6490f4ca45217c7df6a58f43aa7ed385318d60cb0f2f7f880b5f02 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 21 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00003017-202306200-00004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1524-4539 |
| IngestDate | Mon Sep 08 04:32:20 EDT 2025 Mon Jul 21 06:01:32 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 25 |
| Keywords | COVID-19 pre-exposure prophylaxis prevention and control rivaroxaban thrombosis venous thromboembolism |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4694-694bd18c10d6490f4ca45217c7df6a58f43aa7ed385318d60cb0f2f7f880b5f02 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| ORCID | 0000-0002-3175-461X 0000-0003-1407-5276 0000-0001-9109-0811 0000-0001-7744-1486 0000-0002-3413-7836 0000-0002-9860-3584 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC10270282 |
| PMID | 37154020 |
| PQID | 2811567327 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2811567327 pubmed_primary_37154020 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-June-20 |
| PublicationDateYYYYMMDD | 2023-06-20 |
| PublicationDate_xml | – month: 06 year: 2023 text: 2023-June-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Circulation (New York, N.Y.) |
| PublicationTitleAlternate | Circulation |
| PublicationYear | 2023 |
| SSID | ssj0006375 |
| Score | 2.5227633 |
| Snippet | COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1891 |
| SubjectTerms | Anticoagulants - adverse effects COVID-19 Hemorrhage - chemically induced Hemorrhage - drug therapy Hospitalization Humans Outpatients Rivaroxaban - adverse effects Thrombosis - epidemiology Thrombosis - prevention & control |
| Title | Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37154020 https://www.proquest.com/docview/2811567327 |
| Volume | 147 |
| WOSCitedRecordID | wos00003017-202306200-00004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBZtU0IvfSRtk76YQOkpaixLtuxeyrJJSCDZhGXT7m3RkxqyUrpOQtt7_3dHXi85FQo92AdhGSOPZr556BtC3nuRGEaUpzXPPBVMOKpKpmleVoiXC2e96khcT-RoVE2n9XkfcGv7ssqVTuwUtY0mxcj38gqxSyl5Lj9ffaepa1TKrvYtNO6TNY5QJkm1nN6xhZe8I9pFEyWoKHi9TnY6JVGyveHxeHhxsiScPUoRQf4xGeuM_R1pdhbn8Mn_futT8rjHmjBYCsczcs-FDbI5COhnz3_CB-iqP7uw-gZZP-2T7Jvk97i5VYv4Q2kVADEtrGieYoDoYfJtEec64jvhIA23u7BqPtKf6dwFFSzsJ3AJTYCzm-uevbWFrw2ODc--HO9TVn-CAYzx0ThvfjkLPUXpJUzSpnhOLg4PJsMj2ndroAZdbEHx0pZVhmW2FHXmhVECsYE00vpSFRVKhVLSWY4AgVW2zIzOfO6lR1nRhc_yF-RBiMFtEciVscZZXTjmhEYnHWfZ3CteO25dobfJzmrdZ7gbUopDBRdv2tndym-Tl8ufN7ta0nbMuES4iOj41T_Mfk0epb7yqSYsz96QNY-6wL0lD83tddMu3nVihvfR-ekfq6Dc6g |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rivaroxaban+for+Prevention+of+Thrombotic+Events%2C+Hospitalization%2C+and+Death+in+Outpatients+With+COVID-19%3A+A+Randomized+Clinical+Trial&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Piazza%2C+Gregory&rft.au=Spyropoulos%2C+Alex+C&rft.au=Hsia%2C+Judith&rft.au=Goldin%2C+Mark&rft.date=2023-06-20&rft.eissn=1524-4539&rft.volume=147&rft.issue=25&rft.spage=1891&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.123.063901&rft_id=info%3Apmid%2F37154020&rft_id=info%3Apmid%2F37154020&rft.externalDocID=37154020 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1524-4539&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1524-4539&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1524-4539&client=summon |